Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. METHODS: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). RESULTS: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. CONCLUSIONS: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subset of those suffering from Major Depressive Disorder (MDD) achieve remission with antidepressant medication (ADM)1.”
From The relationship between resting-state functional connectivity, antidepressant discontinuation and depression relapse (2020) · cites this paper as [1]
In the citing paper
“about onethird receive no benefit from two or more pharmacologic treatments (Rush et al., 2006;Trivedi et al., 2006).”
From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Rush et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationCUMULATIVE ILLNESS RATING SCALE
LINN, B. S., LINN, M. W., & GUREL, L. (1968) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1968.tb02103.x · Cited by 2,304
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Self-citationAgency for Health Care Policy and Research
Eisenberg, J. M. (1999) · Medical Care · doi:10.1097/00005650-199903000-00001 · Cited by 1,369
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Self-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Self-citation
Research works printed but not linked: 4
- Agency for Health Care Policy and Research. Depression in primary care. Vol. 2. Treatment of major depression. Rockville, Md.: Department of Health and Human Services, 1993. (AHCPR publication no. 93-0551.)
- Fava M, 2000, J Clin Psychiatry, 61, 10
- Joffe RT, 1996, J Clin Psychiatry, 57, 114
- Fava M, 2003, Ann Clin Psychiatry, 15, 17, 10.3109/10401230309085666 · doi:10.3109/10401230309085666 · Paper page
Cited by
Items 701–800 of 999
Zhang, J., Sun, R., Cai, Y., Peng, B., Yang, X., & Gao, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041172 · Cited by 10
Learning Outcomes That Maximally Differentiate Psychiatric Treatments
Strobl, E. V., & Kim, S. (2026) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.70074 · Cited by 6
“…schizophrenia called Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) (Lieberman et al. 2005), and another large‐scale clinical trial of treatment‐resistant depression called Sequenced Treatment Alternatives to Relieve Depression (STAR*D) (Trivedi et al. 2006; Rush et al. 2006).”
Digital Mental Health Education
Daisy, A. (2024) · Advances in educational technologies and instructional design book series · doi:10.4018/979-8-3693-8242-4.ch006 · Cited by 6
Major Depressive Disorder: Epidemiology, Course of Illness, and Treatment
Nierenberg, A. A. (2008) · CNS Spectrums · doi:10.1017/s1092852900002947 · Cited by 4
Self-citationA Perspective on the Emergence of Meditation Techniques for Medical Disorders
Shannahoff‐Khalsa, D. S. (2006) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2006.12.709 · Cited by 5
“The first trial is “The Sequenced Treatment Alternatives to Relieve Depression (STAR*D)” study, which had three levels (level 1 [1], level 2 [2, 3], and level 3 [4]), and was conducted over 6 years at a cost of $35 million.”
Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine.
Pitchot, W., Scantamburlo, G., & Ansseau, M. (2010) · PubMed · Cited by 6
Yoshinaga, H., Masumoto, S., Koyama, K., Kinomura, N., Matsumoto, Y., KATO, T., Baba, S., Matsumoto, K., Horisawa, T., Oki, H., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.10.034 · Cited by 5
Leonard, J. B., & Klein‐Schwartz, W. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1599382 · Cited by 5
“5 mg with titration up to 375 mg per day (3).”
BackgroundPark, C., Zuckerman, H., Subramaniapillai, M., Mansur, R. B., Rosenblat, J. D., Cao, B., Iacobucci, M., Lee, Y. L., Levitan, R. D., Blumberger, D. M., et al. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112767 · Cited by 5
P2X7 in Bipolar and Depressive Disorders
Barron, M. L., Werry, E. L., McGregor, I. S., & Kassiou, M. (2013) · Springer eBooks · doi:10.1007/978-3-642-40282-1_31 · Cited by 6
John, D., Montvida, O., Chin, K. L., Khunti, K., & Paul, S. K. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.06.054 · Cited by 6
A vision of the next generation of behavioral therapies research in the addictions.
Carroll, K., & Rounsaville, B. (2007) · Addiction · doi:10.1176/foc.9.1.foc118 · Cited by 184
Mago, R., Fagiolini, A. M., Weiller, E., & Weiss, C. (2018) · Annals of General Psychiatry · doi:10.1186/s12991-018-0189-z · Cited by 5
Treatment-Resistant Depression: Strategies for Management
Ruelaz, A. R. (2006) · Cited by 5
contact, A. T. O. O. T. I., plan, T. C. S. C. W. T. P. A. P. T. B. O. T. C. R. T. W. B. P. T. C. R. T. A. C. R. I. D. B. L. T. V. B. S. E. S. H. M. C. A. R. R. P. W. E. I. A. T. T., plan, T. S., providers, A. P. T. G. O. T. T. C. S. E. T. S. O. V. R. I. W. B. C. T. T. P. T. C. S. R. P. T. C. W. M., treatment, O. M. H. P. I. I. T., & use., A. A. S. P. C. S. P. A. M. F. P. T. C. C. A. D. I. F. A. H.-R. B. S. A. S. T. O. S. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.3.foc379 · Cited by 5
Sanglier, T., Milea, D., Saragoussi, D., & Toumi, M. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2010.08.009 · Cited by 5
“This finding could be expected, given that there is evidence to suggest that unsatisfactory outcomes and poor tolerability with one SSRI do not preclude a better response with another antidepressant in the same class [22].”
BackgroundPapakostas, G. (2006) · Evidence-Based Mental Health · doi:10.1136/ebmh.9.4.100 · Cited by 6
Curtiss, F. R., & Fairman, K. A. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.5.468 · Cited by 5
Clinical Update on Nursing Home Medicine: 2010
Messinger‐Rapport, B. J., Morley, J. E., Thomas, D. R., & Gammack, J. K. (2010) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2010.08.007 · Cited by 6
Transcranial Magnetic Stimulation: Potential New Treatment for Resistant Depression
Schatzberg, A. F., Demitrack, M. A., O†Reardon, J. P., Richelson, E., & Thase, M. E. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0219 · Cited by 5
Self-citationSTAR*D and Measurement-Based Care for Depression: Don't Toss Out the Baby!
Lam, R. W. M., & Kennedy, S. H. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000103 · Cited by 6
Zhang, H., Wu, Z., Cao, L., Su, Y., Wang, F., Hong, W., Cai, Y., Peng, D., & Fang, Y. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.011 · Cited by 4
Differentially private outcome‐weighted learning for optimal dynamic treatment regime estimation
Spicker, D., Moodie, E. E. M., & Shortreed, S. M. (2024) · Stat · doi:10.1002/sta4.641 · Cited by 8
“Of the 1439 individuals enrolled at level 2, 166 had preferences satisfying the positivity constraints, and of those, n ¼ 109 had complete records for the relevant variates, representing the sample used in these analyses (Rush et al., 2006).”
MethodHough, C. M., Kruse, J. L., Espinoza, R. T., Brooks, J. O., Congdon, E. L., Norris, V., Craske, M. G., & Narr, K. L. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100925 · Cited by 7
Inoue, T., Honda, M., Kawamura, K., Tsuchiya, K., Suzuki, T., Ito, K., Matsubara, R., Shinohara, K., Ishikane, T., Sasaki, K., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.04.001 · Cited by 6
“Some examples are the 49% response rate and 37% remission rate in the largest “real world” study (Rush et al., 2006b).”
BackgroundCognitive Therapy Augmentation versus CT Switch Treatment: A STAR*D Report
Friedman, E. S., Thase, M. E., Wisniewski, S. R., Trivedi, M. H., Biggs, M. M., Fava, M., Warden, D., Niederehe, G., Luther, J. F., & Rush, A. J. (2009) · International Journal of Cognitive Therapy · doi:10.1521/ijct.2009.2.1.66 · Cited by 6
Self-citationDepression in Children and Adolescents: Optimizing Treatment
Tao, R., Moore, J., Mayes, T. L., & Emslie, G. J. (2007) · Pediatric Health · doi:10.2217/17455111.1.2.217 · Cited by 3
“In addition, 17–28% of nonremitters (n = 727), achieved remission after switching to up to 14 weeks of treatment with bupropion, sertraline or venlafaxine [71].”
BackgroundThe Failure of Evidence-Based Medicine to Guide Treatment of Antidepressant Nonresponders
Thase, M. E. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1202 · Cited by 4
“By these standards, it is not certain if either of the augmentation strategies tested in STAR*D would have been more effective than placebo, and neither of the across-class switches offered a 10% advantage over the within-class switch from citalopram to sertraline.(14,15) Another possibility would be to treat patients…”
BackgroundSelf-citationKrupnik, V. (2015) · Journal of EMDR Practice and Research · doi:10.1891/1933-3196.9.3.137 · Cited by 8
“More than 20% of cases do not respond to conventional treatments (Fava, 2003; Rush et al., 2006).”
BackgroundVagus Nerve Stimulation: for Depression and Other Neuropsychiatric Disorders
Howland, R. H. (2006) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20060901-02 · Cited by 4
Kasper, S. F., Bonelli, A., Cattaneo, A., Comandini, A., Dato, G. D., Heiman, F., Pegoraro, V., Palao, D. J., Roca, M., & Volz, H. (2021) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2021.1972120 · Cited by 4
“were also observed in several studies, in which the non-superiority of switching AD classes over continuation of ongoing AD treatment was demonstrated (Ruh e et al. 2006; Rush et al., 2006; Bschor and Baethge 2010; Romera et al. 2012; Schosser et al. 2012; Bschor et al. 2018).”
ResultRitvo, P., Gratzer, D., Knyahnytska, Y., Ortiz, A., Walters, C., Katz, J. D., Laposa, J. M., Baldissera, C., Wayne, N., Pfefer-Litman, D., et al. (2021) · JMIR Research Protocols · doi:10.2196/29726 · Cited by 4
“The exclusion criteria are as follows: (1) individuals currently receiving weekly structured psychotherapy; (2) individuals who meet DSM-V (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) criteria for severe alcohol or substance use disorder (in the past 3 months), borderline personality disorder,…”
BackgroundLohse, M. J., Lorenzen, A., & Müller-Oerlinghausen, B. (2007) · Springer eBooks · doi:10.1007/978-3-540-34370-7_42 · Cited by 5
Kim, E. Y., Kim, S. H., Lee, H. J., Lee, N. Y., Kim, H. Y., Park, C. H. K., & Ahn, Y. M. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.08.057 · Cited by 5
Carrico, W. T., Georgette, G., Madore, M. R., Kozel, F. A., George, M. S., Lindley, S., Lovett, S., Yoon, J. H., & Yesavage, J. A. (2020) · Federal Practitioner · doi:10.12788/fp.0004 · Cited by 7
Antai-Otong, D. (2007) · Perspectives In Psychiatric Care · doi:10.1111/j.1744-6163.2007.00123.x · Cited by 5
Depression and anxiety outcomes at a free clinic in a rural state
Burman, M. E., & Petrie, J. L. (2008) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2008.00333.x · Cited by 4
“The appropriateness of prescribing is difficult to determine and complicated by the fact that different classes of antidepressants have similar remission rates in similar clients (Rush et al., 2006).”
BackgroundBareš, M., Novák, T., Kopeček, M., Stopková, P., & Höschl, C. (2010) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2010.492226 · Cited by 4
“CAD was defi ned as a completely new combination of two ADs.”
BackgroundInfluentialSTAR☆D: The Results Begin to Roll in
Menza, M. A. (2006) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.4.4.525 · Cited by 4
Demitrack, M. A. (2010) · Psychopharm Review · doi:10.1097/01.idt.0000369508.83887.db · Cited by 4
Rothberg, B., & Schneck, C. D. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1160-8.10047-8 · Cited by 4
Diagnosis and Treatment of Major Depression 2007
Patricia, D., & Price, D. W. (2007) · The Permanente Journal · doi:10.7812/tpp/07-038 · Cited by 6
Modulation of Inflammation by Antidepressants
Baune, B. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00031-3 · Cited by 5
Romera, I., Luis, M. A., Delgado-Cohen, H., David, P., Ramon, D. J., & Gilaberte, I. (2009) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500802578975 · Cited by 4
“7%) compares favourably with results from the second treatment step of one of the largest depression treatment studies ever conducted, the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project [16,17].”
BackgroundResultFine-tuning our diagnosis and treatment of depression
Ohayon, M. M., & Schatzberg, A. F. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.04.005 · Cited by 4
A Canadian Simulation Model for Major Depressive Disorder: Study Protocol
Ghanbarian, S., Wong, G. W. K., Bunka, M., Edwards, L., Cressman, S., Conte, T., Peterson, S., Vijh, R., Price, M., Schuetz, C., et al. (2024) · PharmacoEconomics - Open · doi:10.1007/s41669-024-00481-y · Cited by 4
“However, >50% of people do not find their first antidepressant medication effective [8], and 30% still do not achieve symptom relief after several different medications [9].”
BackgroundStrony, J. T., Moyal, A. J., Adelstein, J. M., Burkhart, R. J., Imbrogno, A. M., Abid, R., Gillespie, R. J., & Chen, R. E. (2026) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-026-06254-y · Cited by 3
Investigating Resistance to Antidepressants in Animal Models
Peña, J. E., Corbett, B. F., Tamminga, C. A., Bhatnagar, S., & Hitti, F. L. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.04.013 · Cited by 4
Switching antidepressants in patients with treatment-resistant depression
Souery, D., & Pitchot, W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00010-4 · Cited by 3
Collaborative Care for Bipolar Disorder: Part II. Impact on Clinical Outcome, Function, and Costs
Bauer, M. S., McBride, L., Williford, W. O., Glick, H. A., Kinosian, B. P., Altshuler, L. L., Beresford, T. P., Kilbourne, A. M., Sajatovic, M., Coauthors for the Cooperative Studies Program 430 Study Team, et al. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.130114 · Cited by 3
Kim, J.-W., Bae, K., Kim, S., Kang, H., Shin, I., Yoon, J., & Kim, J. (2016) · Psychiatry Investigation · doi:10.4306/pi.2016.13.4.468 · Cited by 3
South, C. C., Rush, A. J., Carmody, T. J., Jha, M. K., & Trivedi, M. H. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s139577 · Cited by 3
Self-citationKeller, C. J., Bhati, M. T., Downar, J. H., & Etkin, A. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615371501.lr30 · Cited by 2
Unmet Needs in the Management of Major Depressive Disorder
(2010) · CNS Spectrums · doi:10.1017/s1092852900027917 · Cited by 3
Wasan, A. D., Edwards, R. R., Kraemer, K. L., Jeong, J., Kenney, M. E., Luong, K., Cornelius, M. C., Mickles, C., Dharmaraj, B., Sharif, E., et al. (2023) · Pain Medicine · doi:10.1093/pm/pnad006 · Cited by 4
“SYNNAPTIC has no strict hierarchical algorithm because only one-third of patients started on any particular AD achieve remission,(65) and there is no strong evidence that one AD is superior to another.(66,67) This flexible prescribing approach is standard in AD trials, such as STAR*D, and mirrors clinical practice.”
Persad, A. R. L., Coote, N. R., Waterhouse, K., McLeod, S., Norton, J. A., Gould, L. A., & Vitali, A. M. (2023) · Brain stimulation · doi:10.1016/j.brs.2023.12.014 · Cited by 4
“Treatment-resistant depression (TRD) occurs in up to one-third of patients with major depressive disorder (MDD) [1].”
Heyman-Kantor, R., Rizk, M., Sublette, M. E., Rubin‐Falcone, H., Yousefzadeh-fard, Y., Burke, A. K., Oquendo, M. A., Sullivan, G. M., Milak, M. S., Zanderigo, F., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.10.071 · Cited by 3
Can (immune and other) gene expression help us to treat depression?
Mariani, N. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100323 · Cited by 3
“Interestingly, Sarubin et al. (2016) looked at the effects of antidepressant therapy on TSPO expression levels in platelets from 37 patients with MDD, comparing TSPO levels in depressed patients before and after 6 weeks of antidepressant treatment.”
[Switch antidepressants: when? How? Why?].
Gourion, D., Galinowski, A., Baraille, L., & Picard, H. (2011) · L'Encephale · doi:10.1016/j.encep.2010.06.008 · Cited by 5
Brain Stimulation Therapies for Mood Disorders: The Continued Necessity of Electroconvulsive Therapy
Nahas, Z. H., & Anderson, B. S. (2011) · Journal of the American Psychiatric Nurses Association · doi:10.1177/1078390311409037 · Cited by 3
Pigott, H., & Alter, G. S. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000323614 · Cited by 3
“p. 394]; yet this article does not report any outcomes, not even for the potential effect modifier of adding trazodone or a sedative to insomniac patients’ antidepressant, which frequently occurred in STAR*D [[”
BackgroundLiu, X., Cui, Z. L., Niu, L., Faries, D. E., Ball, T., & Johnstone, B. M. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.09.027 · Cited by 3
“To ta l 16 ,1 68 (2 9, 52 4) [1 5, 11 4– 17 ,3 78 ] 18 ,5 53 (2 8, 31 1) [1 6, 17 8– 21 14 6] 23 ,2 33 (3 6, 74 6) [2 0, 23 7– 26 ,8 60 ] 0.”
Voice response system to measure healthcare costs: a STAR*D report.
Kashner, T. M., Trivedi, M. H., Wicker, A. B., Fava, M., Greist, J. H., Mundt, J. C., Shores‐Wilson, K., Rush, A. J., & Wisniewski, S. R. (2009) · PubMed · Cited by 4
Self-citationThe Treatment with Exercise Augmentation for Depression (TREAD) study
Rethorst, C. D., Greer, T. L., & Trivedi, M. H. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781316157565.008 · Cited by 3
Self-citationCombining Medications to Achieve Remission
Zajecka, J., & Goldstein, C. (2009) · doi:10.3109/9781420084887-5 · Cited by 4
White Paper: Efficacy of Psychiatric Drugs
Sparks, J. A. (2016) · Ethical Human Psychology and Psychiatry · doi:10.1891/1559-4343.18.1.20 · Cited by 4
Diagnostik und Therapie depressiver Störungen: 2. Teil
Novak, W., Sachs, G., & Erfurth, A. (2017) · psychopraxis neuropraxis · doi:10.1007/s00739-017-0389-3 · Cited by 3
Exercise for Persons with Depression and/or Anxiety Disorders
Rethorst, C. D. (2019) · ACSMʼs Health & Fitness Journal · doi:10.1249/fit.0000000000000463 · Cited by 3
Novitsky, M. A., Sousa, A. D., Asadullin, A. R., Gavrilyuk, O. A., Petrov, A. V., & Nasyrova, R. F. (2021) · Personalized Psychiatry and Neurology · doi:10.52667/2712-9179-2021-1-2-21-45 · Cited by 4
“AADs are often used in patients with major depression, who have an inappropriate response or intolerant ADRs during the use of SSRIs as first-line drugs [112].”
BackgroundEvidence-based pharmacotherapy of major depressive disorder
Dupuy, J. M., Ostacher, M. J., Huffman, J. C., Perlis, R. H., & Nierenberg, A. A. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.005 · Cited by 4
Self-citationBrunoni, A. R. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.47.2012.tde-03122012-110639 · Cited by 4
Hutnyan, M., & McClintock, S. M. (2025) · Transcranial Magnetic Stimulation · doi:10.1016/j.transm.2025.100088 · Cited by 2
Bockting, C., Legemaat, A. M., van der Stappen, J. G. J., Geurtsen, G. J., Semkovska, M., Burger, H., Bergfeld, I. O., Lous, N., Denys, D. A. J. P., & Brouwer, M. E. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063407 · Cited by 2
Musazadeh, V., Faghfouri, A. H., Falahatzadeh, M., Mahmoudinezhad, M., Alizadeh, M., & Shidfar, F. (2026) · Annals of General Psychiatry · doi:10.1186/s12991-026-00676-z · Cited by 3
“Almost half of the major depressive patients do not response to first line treatments such as such as selective serotonin reuptake inhibitors (SSRIs) [4].”
Preskorn, S. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000361280.11210.72 · Cited by 2
Subtypes of Major Depressive Disorder Based on Pharmacological Responsiveness
Preskorn, S. H. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000591 · Cited by 2
Chapter 30. Brain Stimulation Therapies
Keller, C. J., Bhati, M. T., Downar, J. H., & Etkin, A. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372980.lr30 · Cited by 3
Treatment‐resistant depression: where to find hope?
Souery, D. (2023) · World Psychiatry · doi:10.1002/wps.21141 · Cited by 2
Rethorst, C. D., Trombello, J. M., Chen, P. M., Carmody, T. J., Goodman, L. C., Lazalde, A., & Trivedi, M. H. (2024) · BMC Psychology · doi:10.1186/s40359-024-02053-5 · Cited by 4
“It is estimated that only one-third of patients achieve remission following initial treatment, and even following multiple treatment attempts, one-third of patients fail to achieve remission [4–6].”
BackgroundSelf-citationThe Role of Ketamine in Treatment-resistant Depression: A Narrative Review
Reddy, A., Patel, S. G., Barik, A. K., Thappa, P., Jangra, K., Kaur, K., Chauhan, R., & Luthra, A. (2024) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2024.00003 · Cited by 4
Kumar, V., & Doshi, G. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138169 · Cited by 2
A Patient Bill of Rights for Psychotropic Prescription: A Call for a Higher Standard of Care
Duncan, B. L., & Antonuccio, D. O. (2011) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2011.24061 · Cited by 2
“For example, “treatment resistant depression” prompted the STAR*D (Sequenced Treatment Alternatives to Relieve Depression), a study that examined the impact of augmentation or medication switching strategies for depresssion when a traditional regimen of a single SSRI failed [36].”
Sen, S., & Prabhu, M. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318253d737 · Cited by 2
“Mixed (2) Either the ‘‘experimental’’ medication was no different from the studied alternative or the ‘‘experimental’’ medication was superior to the studied alternative for 1 or more outcome measures but inferior for other outcome measures.”
BackgroundMartin, B., Quilès, C., & Schaer, V. (2014) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2014.08.017 · Cited by 2
Han, K., Park, S., Won, E., Sung, S.-H., Lee, H., Koo, J.-W., Lee, K., Lee, H.-Y., Paik, J., Jeon, H. J., et al. (2013) · 신경정신의학 · doi:10.4306/jknpa.2013.52.5.386 · Cited by 2
Greer, T. L., & Trivedi, M. H. (2014) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.12.2.146 · Cited by 2
Self-citationSTAR*D: Lessons Learned for Primary Care
Ziffra, M., & Gilmer, W. S. (2007) · Primary psychiatry · Cited by 2
Shrinking Health Care Disparities in Women: The Depression Dilemma
Alexander, J. L., Keita, G. P., Toney, S. D., & Golinkoff, M. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.9-a.1 · Cited by 2
Fleck, M. P., Berlim, M. T., Lafer, B., Sougey, É. B., Porto, J. A. D., Brasil, M. A. A., Juruena, M. F., & Hetem, L. A. (2009) · Cited by 10
Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
Hodgkin, D., Horgan, C. M., Creedon, T. B., Merrick, E. L., & Stewart, M. T. (2015) · PubMed · Cited by 2
Recent advances in the biological treatment of mood disorders
McDonald, G., & Hallahan, B. P. (2009) · Irish Journal of Psychological Medicine · doi:10.1017/s0790966700000331 · Cited by 2
Further research needed for severe and chronic depression in specialist mental health services
Lewis, G. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30213-9 · Cited by 2
Pharmacogenomics Applications in Psychiatric Disorders
Lencz, T., & Malhotra, A. K. (2008) · Methods in pharmacology and toxicology · doi:10.1007/978-1-59745-439-1_17 · Cited by 2
What Treatments Are Effective for Depression in the Palliative Care Setting?
Irwin, S. A., & Block, S. D. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-3796-7.00033-1 · Cited by 2
Combination Strategies in Treatment-Resistant Depression
Lopez-Munoz, F. J., Álamo, C., & García‐García, P. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_28 · Cited by 3
Firouzabadi, N., Asadpour, R., & Zomorrodian, K. (2020) · Galen Medical Journal · doi:10.31661/gmj.v9i0.1781 · Cited by 2
“Development of SSRIs with high efficacy and few associated side effects is an important achievement in treatment of depression [16, 17].”
BackgroundVortioxetine: a comprehensive update on a new-generation antidepressant
Evren, C. (2021) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.14744/dajpns.2021.00115 · Cited by 2
Carcamo, A., Kemper, F., & Mauricio, D. (2021) · IEEE Sciences and Humanities International Research Conference (SHIRCON) · doi:10.1109/shircon53068.2021.9652293 · Cited by 4
Little, J. W., Falace, D. A., Miller, C. S., & Rhodus, N. L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-323-08028-6.00029-4 · Cited by 2
Metadata
- Authors
- Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., Shores-Wilson, K., Niederehe, G., & Fava, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- New York State Psychiatric Institute (US)
- Massachusetts General Hospital (US)
- National Institute of Mental Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1231-1242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140787893
- Cited by
- 1,033
- References
- 44
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 28 · 2021: 46 · 2020: 43 · 2019: 54 · 2018: 51 · 2017: 35 · 2016: 42 · 2015: 45 · 2014: 46 · 2013: 45 · 2012: 43
- FWCI
- 66.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, antidepressant switching, bupropion, sertraline, venlafaxine, treatment-resistant depression, symptom remission, antidepressant response, outpatients
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Female, Humans, Male, Remission Induction, Time Factors, Bupropion, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.